OHC to Exclusively Offer Paxman Scalp Cooling to Help Prevent Hair Loss Caused by Certain Chemotherapy Drugs
FOR IMMEDIATE RELEASE
OHC Marketing Department
513-751-2273 ext. 10204
Cincinnati, Aug. 16, 2017 — The first question that people generally ask about chemotherapy is whether or not they will lose their hair. Many patients rank hair loss as their most feared and experienced side effect of chemotherapy treatment. The psychological effect is high and can have a dramatic impact on self-esteem.
OHC, the region’s premier source of treatment for nearly every form of cancer and complex blood disorder, will be the exclusive regional provider of the Paxman Scalp Cooling System. Also known as the ‘cold cap’, scalp cooling can be used to combat chemotherapy-induced alopecia (hair loss) and has a positive impact on the confidence, strength and hope of the people that choose to use it.
Chemotherapy works by targeting all rapidly dividing cells in the body. Hair is the second fastest dividing cell and this is the reason why many chemotherapy drugs cause alopecia (hair loss). The hair follicles in the growth phase are attacked, resulting in hair loss approximately two weeks after chemotherapy is completed.
Scalp cooling works by reducing the temperature of the scalp by a few degrees immediately before, during and after the administration of chemotherapy. This in turn reduces the blood flow to hair follicles, which may prevent or minimize the hair loss. Although successful scalp cooling depends on many factors, research and studies have shown that scalp cooling can be effective across a wide range of chemotherapy regimen.
“We have had patients consider skipping chemotherapy due to the possibility of hair loss,” says Karen Dyehouse, MD, Oncology-Hematology with OHC. “For some women, it has a strong impact because their hair is part of who they are. One woman said she had always had long brown hair. It’s how her small children know her. She didn’t want them to have memories of her in wigs and hats or nothing. For these women, and men, we can now offer them an option.”
Typically, patients select four treatments, which cost $1300. Contact your insurance carrier to see if the cost is covered. You may be eligible for a financial assistance program. Contact Paxman to learn more.
As scalp cooling has been used since the 1970s, the associated side effects of cold caps are well-known. Short to medium-term side effects include cold discomfort, headache, forehead pain and dizziness or light-headedness.
These side effects are temporary and usually only happen during the scalp cooling process. Patients who are known to be, or suspected of being, affected with cold urticaria (an allergic reaction to cold temperature, which results in welts on the skin) or cold agglutinin disease (high concentrations of circulating antibodies to red blood cells) should not use scalp cooling and the cold cap. There is only one known potential long-term side effect. Although extremely rare (<2.5%), scalp cooling, when used on patients receiving chemotherapy for breast cancer, could potentially lead to an increased rate of scalp metastases. The Paxman Scalp Cooling system in the U.S. has been FDA cleared for breast cancers. Its use at OHC will be offered to those breast cancer patients whose treatment regimen will include drugs likely to induce Alopecia (Taxanes and Arthracycline based regimens).